<unk>  (RSDN), is a minimally invasive, endovascular catheter based procedure using radiofrequency ablation or ultrasound ablation aimed at treating resistant hypertension (high blood pressure not controlled by medication). Nerves in the wall of the<unk>  artery are ablated by applying radiofrequency pulses or ultrasound to the<unk>  arteries. This causes reduction of<unk>  afferent and efferent activity to the kidney and blood pressure can be decreased. Early data from international clinical trials without sham controls was promising - demonstrating large blood pressure reductions in patients with treatment-resistant hypertension. However, in 2014 a prospective, single-blind, randomized, sham-controlled clinical trial failed to confirm a beneficial effect on blood pressure. A 2014 consensus statement from The Joint UK Societies did not recommend the use of<unk><unk>  for treatment of resistant hypertension on current evidence. More recent sham-controlled trials suggest<unk><unk>  can lead to lower systolic blood pressure.
Renal sympathetic denervation
Urinary diversion
Uterus transplantation
Tubuloglomerular feedback
Renal replacement therapy
Diuresis
Ureteroureterostomy
Dopamine therapy